Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International Study for Treatment of Standard-Risk Childhood Relapsed ALL 2010
2012-000793-30Phase 3Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide, cytarabine, daunorubicin, dexamethasone, etoposide and 11 more in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Event-free survival superiority. Started Dec 2012; status: completed.
02
Drugs
cyclophosphamidecytarabinedaunorubicindexamethasoneetoposide
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2012-000793-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000793-30.